Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta. Aug. 29, 2022 6:30 AM ET Kineta, Inc. (KANT) ...

Seattle biotech company Kineta is going public through a merger with Yumanity Therapeutics, a neurosciences company based in Boston.Yumanity will also sell part of its pipeline to Johnson ...

Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investors: Burns McClellan, Inc. Lee Roth [email protected] ...

--Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today ...

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV ...

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV ...

Yumanity Therapeutics is cutting 60% of its workforce by April, while not-so-subtly asking for buyers as the neurodegenerative-focused biotech's early promise begins to fade.

About YTX-7739 YTX-7739 is Yumanity Therapeutics’ proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target ...

The raise comes after Kineta went public in December through a reverse merger with Boston-based biotech Yumanity Therapeutics Inc. Seattle-based biotech Kineta Inc. has raised about $6 million ...

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for YMTX is 37.9.